已收盘 08-21 16:00:00 美东时间
+0.053
+0.09%
NRx Pharmaceuticals 2026财年第二季度业绩电话会议讨论了2670万美元的现金储备、KETAFREE的FDA进展、SPARC-TMS试验以及GeNeuro的ALS(渐冻症)项目。
08-17 23:43
NRx Pharmaceuticals’ Q2 2026 earnings call covered $26.7 million in cash, KETAFREE FDA progress, the SPARC-TMS trial and GeNeuro’s ALS program.
08-17 23:42
Rocket Lab (RKLB) secured a $397M contract from the U.S. Space Force to develop, launch and operate multiple Flatellites for the Space-Based Airborne Moving Target Indicator (SB-AMTI) program. Under t...
08-05 14:27
Infleqtion (INFQ) has emerged as the only publicly traded neutral atom play, and the analysts at Wedbush believe it is a compelling way to gain exposure to quantum computing. Wedbush initiated coverag...
06-26 22:53